Field Diagnostics for Pathogen Identification and Surveillance

病原体识别和监测的现场诊断

• 批准号: 9387011
• 负责人: DONALD SAMUEL GRANT
• 金额: $ 37.71万
• 依托单位: REDEEMER'S UNIVERSITY
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/9387011
• 关键词: Address; Africa; Antigens; Authorization documentation; Biological Assay; Case Fatality Rates; Collaborations; Communicable Diseases; Detection; Development; Devices; Diagnosis; Diagnostic; Diagnostic tests; Disease; Ebola virus; Emergency Situation; Enzyme-Linked Immunosorbent Assay; Enzymes; Epidemiology; Fever; Fever of Unknown Origin; Genetic; Genomics; Government; Health; Hospitals; Immunoassay; Immunology; Immunosorbents; Industry; Investigation; Laboratories; Lassa Fever; Lassa virus; Lateral; Lead; Leptospirosis; Link; Liquid substance; Malaria; Microbe; Nigeria; Nucleic Acids; Patients; Polymerase Chain Reaction; Procedures; Psychological Transfer; Recombinants; Research; Research Personnel; Rhabdoviridae; Rickettsia Infections; Sampling; Scientist; Senegal; Sepsis; Sierra Leone; Site; Syndrome; Technical Expertise; Technology; Technology Transfer; Testing; Training; Triage; Typhoid Fever; Validation; Viral Hemorrhagic Fevers; Virus Diseases; Work; Yellow Fever; base; burden of illness; clinical care; clinical practice; clinical research site; design; diagnostic assay; experience; genome wide association study; improved; interest; microbial; multidisciplinary; next generation; novel; novel virus; operation; pathogen; point of care; rapid diagnosis; sample collection; ward

Project Summary — Project 2 Approximately two-thirds of suspected VHF patients referred to our VHF Wards in Sierra Leone and Nigeria test negative for either Lassa virus (LASV) or Ebola virus (EBOV) infection. In our clinical practices we consider these patients to have a fever of unknown origin (FUO). ​Next generation genomics analyses will be used in Project 1 to define the range of microbial pathogens inducing febrile illnesses in patients presenting to three established VHF clinical sites across West Africa. Project 2 will extend these studies by transferring technical expertise for designing and validating field deployable polymerase chain reaction (PCR) based nucleic acid assays and recombinant antigen based immunoassays. In Milestone 1 we will transfer technology and provide training for the development and validation of field deployable quantitative PCR tests for known and novel pathogens to enhance clinical care. Transfer of technology and training for the development and validation of field deployable immunoassays for known and novel pathogens to allow for rapid diagnosis across many sites will be provided in Milestone 2. In Milestone 3 we will perform sample collection, surveillance and investigation of the epidemiology of known and novel pathogens in Senegal, Sierra Leone and Nigeria. The availability of these diagnostic assays will improve clinical care, and enable enhanced surveillance and investigation of the epidemiology of known and novel viruses, as well as other microbial pathogens contributing to the infectious disease burden in West Africa. 1

项目总结——项目 2 大约三分之二的疑似甚高频患者被转诊至我们位于塞拉利昂的甚高频病房 尼日利亚的拉沙病毒（LASV）或埃博拉病毒（EBOV）感染检测呈阴性。 临床实践中，我们认为这些患者患有不明原因发烧 (FUO) ​下一步。 项目 1 将使用世代基因组学分析来定义微生物的范围 在三个已建立的 VHF 临床中心就诊的患者中诱发发热性疾病的病原体 项目 2 将通过转移技术专长来扩展这些研究。 设计和验证基于现场可部署聚合酶链式反应 (PCR) 的核酸 在里程碑 1 中，我们将转移基于免疫分析和重组抗原的分析。 技术并为现场部署的开发和验证提供培训 对已知和新型病原体进行 PCR 检测，以加强临床护理的转移。 现场可部署免疫测定的开发和验证的技术和培训 将提供已知和新型病原体的信息，以便在许多地点进行快速诊断 里程碑 2. 在里程碑 3 中，我们将进行样本收集、监测和调查 塞内加尔、塞拉利昂和尼日利亚已知和新型病原体的流行病学。 这些诊断测定的可用性将改善临床护理，并能够增强 对已知和新型病毒以及其他病毒的流行病学进行监测和调查 造成西非传染病负担的微生物病原体。 1